

David N Church

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4606415/david-n-church-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

2,828
citations

26
h-index

53
g-index

58
ext. papers

3,847
ext. citations

10.2
avg, IF

4.76
L-index

#	Paper	IF	Citations
51	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients.. <i>Nature Communications</i> , 2022 , 13, 1373	17.4	3
50	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021 , 124, 1759-1776	8.7	19
49	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021 , 127, 2409-2422	6.4	14
48	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. <i>British Journal of Cancer</i> , 2021 , 124, 786-796	8.7	2
47	Automated assessment of CD8 T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. <i>EBioMedicine</i> , 2021 , 71, 103547	8.8	1
46	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2020 , 6, 283-296	5.3	8
45	The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability. <i>Clinical Epigenetics</i> , 2020 , 12, 102	7.7	2
44	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. <i>Lancet, The</i> , 2020 , 395, 350-360	40	142
43	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. <i>Cancer Immunology Research</i> , 2020 , 8, 1508-1519	12.5	14
42	Interpretation of somatic POLE mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020 , 250, 323-335	9.4	70
41	Clinicopathological and molecular characterisation of Smultiple-classifierSendometrial carcinomas. <i>Journal of Pathology</i> , 2020 , 250, 312-322	9.4	83
40	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. <i>ESMO Open</i> , 2020 , 5, e001040	6	0
39	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. <i>ESMO Open</i> , 2020 , 5,	6	22
38	A Transcriptionally Distinct CXCL13CD103CD8 T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 784-796	12.5	53
37	Tumour-infiltrating CD8 lymphocytes and colorectal cancer recurrence by tumour and nodal stage. <i>British Journal of Cancer</i> , 2019 , 121, 474-482	8.7	15
36	ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. <i>Cancer Medicine</i> , 2019 , 8, 6305-6314	4.8	3
35	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2019 , 25, 1087-1097	12.9	58

34	Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. <i>Journal of Pathology</i> , 2018 , 245, 283-296	9.4	43
33	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018 , 4,	2.8	11
32	Adjuvant Treatment for Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. <i>Clinical Cancer Research</i> , 2018 , 24, 3197-3203	12.9	30
31	Tumour-infiltrating CD8+ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3515-3515	2.2	2
30	Changing Practice Evaluation-Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols-Experience From a Supraregional Center. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 240-244	3.3	4
29	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 635-643	18.8	40
28	Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 152-156	3.3	17
27	Hypermutated Colorectal Cancer and Neoantigen Load 2017 , 187-215		2
26	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncolmunology</i> , 2017 , 6, e1264565	7.2	79
25	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. <i>Oncolmunology</i> , 2017 , 6, e1338230	7.2	78
24	Cancer predisposition syndromes: lessons for truly precision medicine. <i>Journal of Pathology</i> , 2017 , 241, 226-235	9.4	10
23	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1543-1557	21.7	94
22	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. <i>Nature Communications</i> , 2016 , 7, 111111	17.4	54
21	A panoply of errors: polymerase proofreading domain mutations in cancer. <i>Nature Reviews Cancer</i> , 2016 , 16, 71-81	31.3	205
20	Vaccination of chemotherapy patients--effect of guideline implementation. <i>Supportive Care in Cancer</i> , 2016 , 24, 2317-2321	3.9	10
19	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016 , 29, 174-81	9.8	42
18	proofreading mutation, immune response and prognosis in endometrial cancer. <i>Oncolmunology</i> , 2016 , 5, e1072675	7.2	26
17	Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers. <i>JAMA Oncology</i> , 2016 , 2, 141	13.4	1

16	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016 , 48, 667-674	36.3	56
15	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 207-216	18.8	160
14	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015 , 28, 836-44	9.8	222
13	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3347-3355	12.9	184
12	Prognostic significance of POLE proofreading mutations in endometrial cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 402	9.7	169
11	Toxicogenomics: an unmet need in cancer medicine. <i>Nature Reviews Cancer</i> , 2014 , 14, 440-5	31.3	24
10	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1031-9	2.2	164
9	Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 363-371	1	3
8	What is the extent of the advantage of video-assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non-small-cell lung cancer resection?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014 , 19, 656-60	1.8	15
7	Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4297-305	2.2	156
6	In reply: response to Marioni. <i>Current Oncology Reports</i> , 2013 , 15, 3	6.3	
5	DNA polymerase β and ϵ exonuclease domain mutations in endometrial cancer. <i>Human Molecular Genetics</i> , 2013 , 22, 2820-8	5.6	236
4	Survivin in solid tumors: rationale for development of inhibitors. <i>Current Oncology Reports</i> , 2012 , 14, 120-8	6.3	88
3	A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S35		
2	Extended survival in women with brain metastases from HER2 overexpressing breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 250-4	2.7	61
1	Clinical review - small cell carcinoma of the bladder. <i>Cancer Treatment Reviews</i> , 2006 , 32, 588-93	14.4	31